|Bid||0.9000 x 100|
|Ask||0.9200 x 2500|
|Day's Range||0.8900 - 0.9104|
|52 Week Range||0.5000 - 4.9300|
|PE Ratio (TTM)||-0.97|
|Earnings Date||Nov 11, 2016 - Nov 14, 2016|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
Acer Therapeutics, a three-year-old Cambridge biotech developing drugs for ultra-rare diseases, said Monday that it will go public through a reverse merger with a small Texas company. Acer said it would merge with Opexa Therapeutics (OPXA), which laid off all but two of its 20 employees after its lead drug for multiple sclerosis flunked a mid-stage trial in October. In connection with the deal, Acer said it would receive a $15.7 million round of financing led by TVM Capital, a life sciences venture firm based in Germany.
After consummation Opexa's name will be changed to Acer Therapeutics Inc.